Reducing iron accumulation: A potential approach for the prevention and treatment of postmenopausal osteoporosis (Review)

Chen,Bin; Li,Guang‑Fei; Shen,Ying; Huang,Xi; Xu,You‑Jia

doi:10.3892/etm.2015.2484

Reducing iron accumulation: A potential approach for the prevention and treatment of postmenopausal osteoporosis (Review)

Authors:
- Bin Chen
- Guang‑Fei Li
- Ying Shen
- Xi Huang
- You‑Jia Xu
View Affiliations

Affiliations: Department of Orthopedics, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China, Division of Rheumatology, NYU Hospital for Joint Diseases, New York, NY 10003, USA
Published online on: May 8, 2015 https://doi.org/10.3892/etm.2015.2484
Pages: 7-11

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Postmenopausal osteoporosis (PMOP) is a systemic bone metabolism disease, characterized by progressive bone loss following menopause and a subsequent increase in fracture risk. Estrogen deficiency as a result of menopause is known to increase bone resorption and accelerate bone loss. Furthermore, postmenopausal women may exhibit iron accumulation, in addition to estrogen deficiency. Elevated iron levels are a risk factor for PMOP in postmenopausal women, and reducing the iron overload has been demonstrated to benefit bone cell metabolism in vitro and improve the bone in vivo by normalizing osteoclastic bone resorption and formation. The identification of hepcidin was a key development in the field of iron metabolism in the previous decade. We hypothesize that hepcidin may aid in the prevention and treatment of PMOP due to its capacity to control body iron stores and its intrinsic effects on osteoblast function. The aim of the current review was to highlight the role of iron accumulation in the pathogenesis of PMOP and to evaluate the possible use of hepcidin as a potential therapy for this condition.

View Figures

View References

1	MacKenzie EL, Iwasaki K and Tsuji Y: Intracellular iron transport and storage: From molecular mechanisms to health implications. Antioxid Redox Signal. 10:997–1030. 2008. View Article : Google Scholar : PubMed/NCBI
2	Olivieri NF, Liu PP, Sher GD, et al: Brief report: Combined liver and heart transplantation for end-stage iron-induced organ failure in an adult with homozygous beta-thalassemia. N Engl J Med. 330:1125–1127. 1994. View Article : Google Scholar : PubMed/NCBI
3	Kohgo Y, Ikuta K, Ohtake T, Torimoto Y and Kato J: Body iron metabolism and pathophysiology of iron overload. Int J Hematol. 88:7–15. 2008. View Article : Google Scholar : PubMed/NCBI
4	Weinberg ED: Iron loading: A risk factor for osteoporosis. Biometals. 19:633–635. 2006. View Article : Google Scholar : PubMed/NCBI
5	Weinberg ED: Role of iron in osteoporosis. Pediatr Endocrinol Rev. 6:(Suppl 1). 81–85. 2008.PubMed/NCBI
6	Jian J, Pelle E and Huang X: Iron and menopause: Does increased iron affect the health of postmenopausal women? Antioxid Redox Signal. 11:2939–2943. 2009. View Article : Google Scholar : PubMed/NCBI
7	Tsay J, Yang Z, Ross FP, et al: Bone loss caused by iron overload in a murine model: Importance of oxidative stress. Blood. 116:2582–2589. 2010. View Article : Google Scholar : PubMed/NCBI
8	de Vernejoul MC, Pointillart A, Golenzer CC, et al: Effects of iron overload on bone remodeling in pigs. Am J Pathol. 116:377–384. 1984.PubMed/NCBI
9	Adams PC and Chakrabarti S: Genotypic/phenotypic correlations in genetic hemochromatosis: Evolution of diagnostic criteria. Gastroenterology. 114:319–323. 1998. View Article : Google Scholar : PubMed/NCBI
10	Zacharski LR, Ornstein DL, Woloshin S and Schwartz LM: Association of age, sex, and race with body iron stores in adults: Analysis of NHANES III data. Am Heart J. 140:98–104. 2000. View Article : Google Scholar : PubMed/NCBI
11	Huang X, Xu Y and Partridge NC: Dancing with sex hormones, could iron contribute to the gender difference in osteoporosis? Bone. 55:458–460. 2013. View Article : Google Scholar : PubMed/NCBI
12	Xu YJ, Sirois P and Li K: Iron overload plays a unique role in osteoporosis. Blood (E-letter). http://www.bloodjournal.org/content/116/14/2582.e-letters#iron-overload-plays-a-unique-role-in-osteoporosisAccessed. May 6–2015
13	Kim BJ, Ahn SH, Bae SJ, et al: Iron overload accelerates bone loss in healthy postmenopausal women and middle-aged men: A 3-year retrospective longitudinal study. J Bone Miner Res. 27:2279–2290. 2012. View Article : Google Scholar : PubMed/NCBI
14	Kim BJ, Lee SH, Koh JM and Kim GS: The association between higher serum ferritin level and lower bone mineral density is prominent in women ≥45 years of age (KNHANES 2008–2010). Osteoporos Int. 24:2627–2637. 2013. View Article : Google Scholar : PubMed/NCBI
15	Clark SF: Iron deficiency anemia. Nutr Clin Pract. 23:128–141. 2008. View Article : Google Scholar : PubMed/NCBI
16	Zimmermann MB and Hurrell RF: Nutritional iron deficiency. Lancet. 370:511–520. 2007. View Article : Google Scholar : PubMed/NCBI
17	Yang Q, Jian J, Katz S, Abramson SB and Huang X: 17beta-Estradiol inhibits iron hormone hepcidin through an estrogen responsive element half-site. Endocrinology. 153:3170–3178. 2012. View Article : Google Scholar : PubMed/NCBI
18	Hou Y, Zhang S, Wang L, et al: Estrogen regulates iron homeostasis through governing hepatic hepcidin expression via an estrogen response element. Gene. 511:398–403. 2012. View Article : Google Scholar : PubMed/NCBI
19	Isomura H, Fujie K, Shibata K, et al: Bone metabolism and oxidative stress in postmenopausal rats with iron overload. Toxicology. 197:93–100. 2004. View Article : Google Scholar : PubMed/NCBI
20	Kalinowski DS and Richardson DR: The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev. 57:547–583. 2005. View Article : Google Scholar : PubMed/NCBI
21	Bennett CN, Longo KA, Wright WS, et al: Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA. 102:3324–3329. 2005. View Article : Google Scholar : PubMed/NCBI
22	Almeida M, Han L, Martin-Millan M, O'Brien CA and Manolagas SC: Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem. 282:27298–27305. 2007. View Article : Google Scholar : PubMed/NCBI
23	Jia P, Xu YJ, Zhang ZL, et al: Ferric ion could facilitate osteoclast differentiation and bone resorption through the production of reactive oxygen species. J Orthop Res. 30:1843–1852. 2012. View Article : Google Scholar : PubMed/NCBI
24	Liu G, Men P, Kenner GH and Miller SC: Age-associated iron accumulation in bone: implications for postmenopausal osteoporosis and a new target for prevention and treatment by chelation. Biometals. 19:245–251. 2006. View Article : Google Scholar : PubMed/NCBI
25	Liu G, Men P, Kenner GH and Miller SC: Therapeutic effects of an oral chelator targeting skeletal tissue damage in experimental postmenopausal osteoporosis in rats. Hemoglobin. 32:181–190. 2008. View Article : Google Scholar : PubMed/NCBI
26	Maggio A, Filosa A, Vitrano A, et al: Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells Mol Dis. 47:166–175. 2011. View Article : Google Scholar : PubMed/NCBI
27	Fabio G, Minonzio F, Delbini P, Bianchi A and Cappellini MD: Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). Blood. 109:362–364. 2007. View Article : Google Scholar : PubMed/NCBI
28	Kalpatthi R, Peters B, Kane I, et al: Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease. Pediatr Blood Cancer. 55:1338–1342. 2010. View Article : Google Scholar : PubMed/NCBI
29	Ishii KA, Fumoto T, Iwai K, et al: Coordination of PGC-1beta and iron uptake in mitochondrial biogenesis and osteoclast activation. Nat Med. 15:259–266. 2009. View Article : Google Scholar : PubMed/NCBI
30	Ganz T: Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 102:783–788. 2003. View Article : Google Scholar : PubMed/NCBI
31	Donovan A, Brownlie A, Zhou Y, et al: Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature. 403:776–781. 2000. View Article : Google Scholar : PubMed/NCBI
32	Nemeth E, Tuttle MS, Powelson J, et al: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 306:2090–2093. 2004. View Article : Google Scholar : PubMed/NCBI
33	Lesbordes-Brion JC, Viatte L, Bennoun M, et al: Targeted disruption of the hepcidin 1 gene results in severe hemochromatosis. Blood. 108:1402–1405. 2006. View Article : Google Scholar : PubMed/NCBI
34	Nicolas G, Bennoun M, Devaux I, et al: Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA. 98:8780–8785. 2001. View Article : Google Scholar : PubMed/NCBI
35	Hadziahmetovic M, Song Y, Ponnuru P, et al: Age-dependent retinal iron accumulation and degeneration in hepcidin knockout mice. Invest Ophthalmol Vis Sci. 52:109–118. 2011. View Article : Google Scholar : PubMed/NCBI
36	Roetto A, Papanikolaou G, Politou M, et al: Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet. 33:21–22. 2003. View Article : Google Scholar : PubMed/NCBI
37	Ahmad KA, Ahmann JR, Migas MC, et al: Decreased liver hepcidin expression in the Hfe knockout mouse. Blood Cells Mol Dis. 29:361–366. 2002. View Article : Google Scholar : PubMed/NCBI
38	Guggenbuhl P, Fergelot P, Doyard M, et al: Bone status in a mouse model of genetic hemochromatosis. Osteoporos Int. 22:2313–2319. 2011. View Article : Google Scholar : PubMed/NCBI
39	Nicolas G, Viatte L, Lou DQ, et al: Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet. 34:97–101. 2003. View Article : Google Scholar : PubMed/NCBI
40	Moran-Jimenez MJ, Mendez M, Santiago B, et al: Hepcidin treatment in Hfe-/- mice diminishes plasma iron without affecting erythropoiesis. Eur J Clin Invest. 40:511–517. 2010. View Article : Google Scholar : PubMed/NCBI
41	Gardenghi S, Ramos P, Marongiu MF, et al: Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice. J Clin Invest. 120:4466–4477. 2010. View Article : Google Scholar : PubMed/NCBI
42	Andrews NC: Closing the iron gate. N Engl J Med. 366:376–377. 2012. View Article : Google Scholar : PubMed/NCBI
43	Ganz T and Nemeth E: The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology Am Soc Hematol Educ Program. 2011:538–542. 2011. View Article : Google Scholar : PubMed/NCBI
44	Li GF, Pan YZ, Sirois P, Li K and Xu YJ: Iron homeostasis in osteoporosis and its clinical implications. Osteoporos Int. 23:2403–2408. 2012. View Article : Google Scholar : PubMed/NCBI
45	Ma Y, Xu YJ, Wang AD, Yu C, Wang B, Zhang P and Zhang ZD: A preliminary report of expression of hepcidin gene in SD rats osteoporosis model. Su Zhou Da Xue Zue Bao. 26:367–369. 2006.(In Chinese).
46	Zhang P, Xu YJ, Zhao DY, et al: Increased intracellular iron and mineralization of cultured hFOB 1.19 cells following hepcidin activation through ferroportin-1. Saudi Med J. 31:1303–1308. 2010.PubMed/NCBI
47	Li GF, Xu YJ, He YF, et al: Effect of hepcidin on intracellular calcium in human osteoblasts. Mol Cell Biochem. 366:169–174. 2012. View Article : Google Scholar : PubMed/NCBI
48	Xu Y, Li G, Du B, et al: Hepcidin increases intracellular Ca²⁺ of osteoblast hFOB1.19 through L-type Ca²⁺ channels. Regul Pept. 172:58–61. 2011. View Article : Google Scholar : PubMed/NCBI
49	Xi Huang: Treatment of osteoporosis in peri- and post-menopausal women with hepcidin. US Patent 0,204,122. Filed. February 11–2010 issued. August 12–2010
50	De Domenico I, Lo E, Ward DM and Kaplan J: Hepcidin-induced internalization of ferroportin requires binding and cooperative interaction with Jak2. Proc Natl Acad Sci USA. 106:3800–3805. 2009. View Article : Google Scholar : PubMed/NCBI
51	De Domenico I, Zhang TY, Koening CL, et al: Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J Clin Invest. 120:2395–2405. 2010. View Article : Google Scholar : PubMed/NCBI
52	Bellido T, Borba VZ, Roberson P and Manolagas SC: Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation. Endocrinology. 138:3666–3676. 1997. View Article : Google Scholar : PubMed/NCBI
53	Nishimura R, Moriyama K, Yasukawa K, Mundy GR and Yoneda T: Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells. J Bone Miner Res. 13:777–785. 1998. View Article : Google Scholar : PubMed/NCBI
54	Barhanpurkar AP, Gupta N, Srivastava RK, et al: IL-3 promotes osteoblast differentiation and bone formation in human mesenchymal stem cells. Biochem Biophys Res Commun. 418:669–675. 2012. View Article : Google Scholar : PubMed/NCBI
55	Xu Y, Zhang W, Zhang P, et al: Downregulation of ferroportin 1 expression in hFOB1.19 osteoblasts by hepcidin. Inflammation. 35:1058–1061. 2012. View Article : Google Scholar : PubMed/NCBI
56	Preza GC, Ruchala P, Pinon R, et al: Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. J Clin Invest. 121:4880–4888. 2011. View Article : Google Scholar : PubMed/NCBI
57	Katsumata S, Tsuboi R, Uehara M and Suzuki K: Dietary iron deficiency decreases serum osteocalcin concentration and bone mineral density in Rats. Biosci Biotechnol Biochem. 70:2547–2550. 2006. View Article : Google Scholar : PubMed/NCBI
58	Maurer J, Harris MM, Stanford VA, et al: Dietary iron positively influences bone mineral density in postmenopausal women on hormone replacement therapy. J Nutr. 135:863–869. 2005.PubMed/NCBI